NEW YORK, NY / ACCESSWIRE / December 10, 2019 / The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Aevi Genomic Medicine, Inc. ("Aevi" or the "Company") (NASDAQ:GNMX) stock prior to December 5, 2019.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Aevi to Cerecor Inc. ("Cerecor") (NASDAQ:CERC). Under the terms of the agreement, Aevi stockholders are anticipated to receive up to $0.134 per share in the form of Cerecor stock, after adjusting for Aevi's net assets at closing. To learn more about the action and your rights, go to:
https://www.zlk.com/mna/aevi-genomic-medicine-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.
The Aevi merger investigation concerns whether the Board of Aevi breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Cerecor is underpaying for Aevi shares, thus unlawfully harming Aevi shareholders.
Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP